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ARTICLE
Mapping genomic and transcriptomic alterations
spatially in epithelial cells adjacent to human breast
carcinoma
Moustafa Abdalla1,2,3,4, Danh Tran-Thanh2, Juan Moreno2, Vladimir Iakovlev2, Ranju Nair1, Nisha Kanwar1,2,
Mohamed Abdalla2, Jennifer P.Y. Lee2, Jennifer Yin Yee Kwan2, Thomas R. Cawthorn1,2, Keisha Warren1,
Nona Arneson1, Dong-Yu Wang 1, Natalie S. Fox5,6, Bruce J. Youngson2,7, Naomi A. Miller2,7,
Alexandra M. Easson8, David McCready8, Wey L. Leong8, Paul C. Boutros 5,6,9 & Susan J. Done 1,2,5,7
Almost all genomic studies of breast cancer have focused on well-established tumours
because it is technically challenging to study the earliest mutational events occurring in
human breast epithelial cells. To address this we created a unique dataset of epithelial
samples ductoscopically obtained from ducts leading to breast carcinomas and matched
samples from ducts on the opposite side of the nipple. Here, we demonstrate that pertur-
bations in mRNA abundance, with increasing proximity to tumour, cannot be explained by
copy number aberrations. Rather, we find a possibility of field cancerization surrounding the
primary tumour by constructing a classifier that evaluates where epithelial samples were
obtained relative to a tumour (cross-validated micro-averaged AUC= 0.74). We implement
a spectral co-clustering algorithm to define biclusters. Relating to over-represented bicluster
pathways, we further validate two genes with tissue microarrays and in vitro experiments.
We highlight evidence suggesting that bicluster perturbation occurs early in tumour
development.
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Numerous aberrations have been reported in histologicallynormal epithelium adjacent to breast tumours, includingloss of heterozygosity (LOH), allelic imbalances1–7 and
transcriptomic alterations8–13. These likely represent some of the
earliest genetic alterations in breast carcinogenesis as well as
predisposing factors. However, alterations in normal epithelium
have been elucidated relative to normal breast tissue from other
patients8–10 or with bulk extracted tissue11 making it impossible
to confidently distinguish the earliest changes. Others have sug-
gested that presence of contaminating tumour cells beyond the
invasive tumour margin, rather than field cancerization (i.e.
acquired molecular perturbations over a geographic region sur-
rounding the tumour), may be the cause of local recurrence14.
Here, we develop a map of alterations that occur in breast
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Fig. 1 The first principal component of gene expression directly corresponds to proximity to tumour. a Schematic of the relative locations of all epithelial
sample extractions, with the nipple and tumour highlighted. Samples D1 and D2 were obtained along the duct, approaching the tumour. Sample O1 is an
epithelial sample from a breast duct on the other side of the nipple. b Biplot of the first two principal components of the expression matrix, limited to top
10% most varied genes. This proximity-based separation between epithelial samples is observed with the biplot including all genes, but is clearest here. c
Biplot for the corresponding aCGH data; with no proximity-to-tumour separation in either of the first two principal components. PC, principal component
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Fig. 2 Expression-based classifier can identify where the epithelial samples were obtained from relative to the tumour. a Five-fold cross validation, depicting
the receiver-operating curve (ROC) response of using each patient as a test; mean micro-average AUC= 0.74. b Original unclustered data set: columns
depicted modules of genes identified through a hierarchical-clustering based gene agglomeration approach and rows corresponding to each epithelial
sample. c Spectral co-clustering reveals biclusters of samples and modules that are both downregulated (modules 4, 6, 12, 13, 15, 18 and 19) and
upregulated (modules 1, 2, 3, 5, 8, 10 and 16) in tumours and adjacent-to-tumour epithelium. All genes in these modules were selected a priori as
univariately informative of the proximity-to-tumour label (top 30% of all genes; see Text). Clustering was done to further reveal structure within these
univariately informative genes. Modules that are downregulated are negatively correlated with proximity to tumour (Table 1), and similarly, modules that
are upregulated are positively correlated with proximity to tumour (Table 1). The sampling clustering has a Rand index of 0.21 with the distance-based
grouping of the samples; the bottom three sample clusters are largely composed of tumour (T) and adjacent-to-tumour epithelial samples (D2). In
contrast, the top cluster is composed largely of distant and contralateral duct epithelial samples (D1 and O1, respectively)
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01357-y ARTICLE
NATURE COMMUNICATIONS |8:  1245 |DOI: 10.1038/s41467-017-01357-y |www.nature.com/naturecommunications 3
epithelium located at various distances from cancers in 8 patients,
using copy number aberrations (CNA) and mRNA profiling, and
microdissected under visual inspection. We evaluated how much
of the variance in mRNA abundance, after adjusting for baseline
levels, can be explained by copy number variation with increasing
proximity to the tumour. We subsequently constructed a multi-
class classifier that could identify from where the epithelial
sample was obtained relative to the tumour; presenting evidence
for field cancerization surrounding the primary tumour. Enrich-
ment analysis of selected biclusters, defined using a spectral co-
clustering algorithm, identifies pathways that may be increasingly
dysregulated with proximity to tumour. Pathway analysis and
enrichment of somatic mutations commonly present in breast
cancer suggests these perturbations were not a consequence of
paracrine influence from the primary tumour. Taken together,
our analyses indicate that tumour initiation may not be driven by
CNAs and that expression data points to an altered field sur-
rounding the tumours. Identifying such transcriptomic altera-
tions, preceding tumourigenesis, would allow us to better
understand carcinoma development as well as develop new
screening and treatment approaches.
Results
Generation of spatial-omic data. To perform a spatial mapping
of samples obtained at increasing distances from the tumour, we
studied eight patients undergoing mastectomy for carcinoma.
During surgery, prior to removal of the breast, a ductoscopy
procedure was performed using a 0.7 mm mammary ductoscope.
The duct leading to the tumour was identified by visual inspec-
tion. Methylene blue dye was injected to identify the involved
duct. Immediately after the mastectomy, epithelial tissue sam-
pling was performed. Two samples were taken along the duct
between the tumour and the nipple (previously dye stained; D1
and D2) and one from a duct on the other side of the nipple
within the same breast (as a normal control; O1). Six samples
were defined as outliers using a sum of standard error boxplot
(Methods section) and were excluded from subsequent analyses.
The epithelial sample closest to tumour (D2) presented with
mixed histology: with some normal (n= 5) and some atypical
ductal hyperplasia (ADH)/ductal carcinoma in situ (DCIS; n= 3).
D1 and O1 were all histologically normal. A sample from the
tumour was also obtained (T; schematic in Fig. 1a). The clinico-
pathological features for this subset are summarised in Supple-
mentary Data 1. To determine the degree and extent of genetic
and molecular alterations along the mammary ducts leading to
the breast cancer, the samples obtained along the duct up to and
including the tumour were then microdissected to ensure >90%
epithelial cells, absence of morphologically malignant cells and
subject to copy number and mRNA abundance profiling.
CNAs explain little spatial heterogeneity in mRNA abundance.
We identified increasing CNAs with proximity to tumour (Sup-
plementary Data 2). To assess whether these genomic changes
had concomitant transcriptomic perturbations, for each sample
from the duct leading to the tumour (D1, D2) and tumour (T), we
performed a regression analysis using the epithelium sample from
the opposite duct (O1) as the predictor of mRNA abundance. The
residuals from this analysis represented a transformed variable
that was used for subsequent modelling; residualising gene
expression on the background sample leaves the part of gene
expression that is unrelated to natural variation and only affected
by the proximity to tumour. A simple regression model demon-
strates that CNAs explain almost none of the variance (equiva-
lently, perturbations) observed in the expression data along the
tumour duct (Supplementary Table 1). Thus, CNAs are not
informative regarding epithelial proximity to tumour. Notably,
however, in some patients, CNAs can explain a small part of the
expression perturbations observed in the tumour itself (T). In
select patients, we detected aberrations across all biopsies sug-
gesting that the CNAs arose during mammary gland development
(similar genes are perturbed across all samples as tabulated in
Supplementary Data 2). However, as evidenced from the models,
CNAs cannot explain the gradual perturbation in mRNA abun-
dance observed with decreasing distance to tumour, suggesting
that their effects on the expression profile may be limited.
Notably, however, we found that the first principal component of
the gene expression matrix separated epithelial samples by their
proximity to the tumour (Fig. 1b).
Expression classifier can identify epithelial sample locations.
Having observed that the first principal component of the
abundance matrix corresponds to distance from tumour, we were
interested in whether mRNA abundance data was sufficiently
informative about tumour proximity. We constructed a multi-
class one versus rest classifier, extending a C-support vector
classification with a linear kernel. To quantify and study the
output of the classifier, we extended ROC curves by considering
each element of the label indicator matrix as a binary predication
(i.e. microaveraging). With this simple classifier, we were able to
obtain an 8-fold cross-validated AUC of 0.74 (each fold was
tested on one patient (i.e. a set of O1, D1, D2 and T from one
individual) and trained on all remaining patients) (Fig. 2a).
Classifier performance was similar between patients with histo-
logically normal D2 (adjacent-to-tumour epithelial samples) and
patients with ADH/DCIS in D2 samples (patients 4, 9 and 14).
Thus, mRNA abundance is sufficiently informative about proxi-
mity to tumour. More generally, this is evidence of field cancer-
ization—there exists transcriptomic perturbations surrounding
the primary tumour that can be detected within expression data
using this classifier. The discriminative ability of the classifier
further suggests that perturbations observed in adjacent-to-
tumour epithelium are likely shared within the cohort (i.e. the
classifier model is generalisable and is not overfitting to single
patient-specific patterns). In other words, this is evidence that
perturbations in epithelial samples that are proximal to the
tumour (i.e. adjacent-to or within the same duct) are shared
across patients. This, alongside the mutation analysis presented
below, suggests that the cancerization is independent of tumour
paracrine influences.
Co-clustering identifies genes that correlate with distance.
Having demonstrated that mRNA abundance is informative with
respect to epithelial distance from tumour, we were interested in
correlating this information with biological and pathway per-
turbation. More concretely, we sought to identify biclusters with
expression values higher (or lower) with samples closer to the
tumour than those further away, using spectral co-clustering.
These biclusters will allow us to delineate which features (genes)
of the transcriptome are informative of epithelial distance to
tumour. For computational feasibility, we limited the abundance
matrix to the top 30% of most informative genes using the uni-
variate non-parametric mutual information estimate imple-
mented for the multi-label classifier. We agglomerated genes into
20 clusters representing modules of genes with the minimum
variance (Ward linkage criterion and Euclidean affinity); 20
clusters maximised the match between the sample clustering and
the distance annotation label using the Adjusted Rand Index
(ARI). ARI is a chance-adjusted similarity measure between two
groupings15. More importantly, no assumption is made on the
underlying structure and it is easy to interpret; an ARI score of 0
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indicating random assignment and a maximum score of 1 indi-
cating perfect overlap. The 20 clusters maximised overlap with
the true proximity-to-tumour annotations (ARI= 0.21; Fig. 2b).
As spectral co-clustering treats the expression matrix as a
bipartite graph (samples and modules representing two sets of
vertices), each sample and each module belong to one bicluster
with higher expression than for any other sample or module
(Fig. 2b). In other words, biclusters represent sets of genes that
are upregulated in a subset of samples; rearrangement of the rows
and columns to make bicluster partitions contiguous reveals high
expression values along the diagonal (Fig. 2b). It is important to
note that all genes in these modules were a priori selected as
informative of proximity-to-tumour label (using the univariate
non-parametric mutual information estimate). Clustering further
reveals structure within these univariately informative genes. To
further quantify the correlation of these modules with proximity
to tumour, we calculated the Pearson correlation between the
module and proximity to tumour (Table 1) and identified nine
significantly correlated modules (after conservative Bonferroni
adjustment). Three modules (6, 13 and 18) negatively correlated
with proximity to tumour and six modules (1, 2, 3, 5, 10 and 16)
correlated positively with proximity to tumour (Table 1).
Transcriptomic alterations are a consequence of cancerization.
Having noted increasing transcriptomic dysregulation with
increasing proximity to tumour, we were interested in establish-
ing whether this mRNA abundance perturbation is a consequence
of contaminating tumour cells, paracrine (secretory) influences
from the tumour or is evidence of field cancerization. As all
specimens were manually microdissected by a pathologist and
obtained under direct vision, the likelihood of tumour cell con-
tamination was low. To distinguish between paracrine and field
cancerization effects, we noted that if modules that correlate with
proximity to tumour are drivers of tumourigenesis, we would
expect a larger number of mutations (such as missense or splice
alterations) in module genes from breast cancer patients com-
pared to background genes that do not belong to these sig-
nificantly correlated modules. If paracrine effects predispose cells
to increased mutations, all genes should be affected equally (i.e.
no enrichment). To test this hypothesis, we collected mutation
data from 8 different breast cancer cohorts, including The Cancer
Genome Atlas16, 17, METABRIC18, and data sets from the
Broad19, Sanger20, and British Columbia Cancer Research Cen-
tre21 (curated by the cBIO Cancer Genomics Portal22). We lim-
ited our analyses to genes that were both present on the
microarray platform and in at least one cohort. We noted that
genes in modules that correlate (positively and) significantly with
proximity to tumour were more likely to be mutated—compared
to all other bicluster genes—in breast cancer patients across all
eight data sets (χ2 test; Yates p< 0.05; odds ratio= 1.33; 95%
confidence interval= (1.18, 1.51); Supplementary Table 2).
A similar trend was noted for modules that negatively and
significantly correlate with proximity to tumour (χ2 test; Yates
p< 0.05; odds ratio= 1.18; 95% confidence interval= (1.01, 1.38);
Supplementary Table 3). This suggests that the observed tran-
scriptomic dysregulation is more likely a consequence of field
cancerization rather than paracrine influence from the primary
tumour.
With this genetic evidence in support of ‘field’ transcriptomic
perturbation, we were subsequently interested in discovering the
functional nature and clinical relevance of the modules
significantly correlated with distance to tumour. No module
stood out with respect to absolute magnitude of the strength of
correlation with proximity to tumour. Thus, we elected to
arbitrarily select two module containing genes for which we had
tissue microarray (TMA) data: module 16 (containing MSI2;
Pearson’s r= 0.63; Bonferroni adjusted p< 0.05) and module 2
(containing SPAG5; Pearson’s r= 0.61; Bonferroni adjusted p<
0.05). Full list of genes and modules is available in Supplementary
Data 3.
MSI2 is a novel member of the Wnt pathway. Since module 16
is positively correlated with proximity to tumour (r= 0.63), we
sought to determine the biological relevance of this mRNA
module and assess whether there was evidence of changes in
pathway activation relative to tumour proximity. The most sta-
tistically significantly over-represented pathway in this module
relative to all others is formation of the “beta-catenin:TCF-
transactivating complex” (q= 5.67 × 10−20), with 25/79 genes in
this pathway that were abundance-profiled as being present in the
289-gene module (expectation is ~1 gene in this pathway).
Complete lists of genes and enriched pathways are available in
Supplementary Data 4 and 5, respectively. Thus, we hypothesised
that the Wnt pathway may be a signalling driver of this module.
A corollary of this is that other genes of this module may be
involved with Wnt signalling through guilt by (coexpression)
association23, i.e. are novel components of the pathway. To par-
tially validate that module is a Wnt signalling module, we selected
a gene not previously associated with Wnt and studied its role in
the pathway: MSI2. MSI2 has an established functional role in
neural stem cell maintenance24 and in the regulation of hema-
topoietic stem cell self-renewal25; MSI2 has also been associated
with other signalling pathways including Hedgehog and Notch26.
Initially, we used activation of a (transcription factor)/LEF-1-
dependent luciferase reporter construct (TOPFLASH) in MCF7
(a luminal breast cancer cell line) to assess the effect of MSI2
overexpression on Wnt signalling. Notably, we observed a
significant 1.5-fold increase in luciferase activity (compared to
control Flag transfections; paired Student’s t test; p< 0.05;
Fig. 3a). Subsequently, to elucidate the mechanism of action of
Table 1 Tabulated summary of Pearson correlation
coefficients between the modules identified with spectral
co-clustering and proximity to tumour, to three significant
digits
Modules Pearson’s r p-value Bonferroni
adjusted
Significant
0 −0.355 0.054 1.075
1 0.597 0.000 0.009 **
2 0.612 0.000 0.006 **
3 0.672 0.000 0.001 **
4 −0.412 0.023 0.460
5 0.542 0.002 0.037 **
6 −0.654 0.000 0.002 **
7 −0.228 0.226 4.519
8 0.460 0.010 0.204
9 0.157 0.406 8.118
10 0.556 0.001 0.027 **
11 0.101 0.595 11.908
12 −0.478 0.007 0.145
13 −0.608 0.000 0.007 **
14 0.173 0.359 7.181
15 −0.383 0.036 0.723
16 0.632 0.000 0.003 **
17 −0.176 0.351 7.016
18 −0.672 0.000 0.001 **
19 −0.511 0.004 0.074
Significant modules are denoted with **. Full list of genes and modules is available in
Supplementary Data 3. All genes in these modules were univariately informative of the
proximity-to-tumour label
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MSI2, its effect on β-catenin was determined. Given the central
role of β-catenin activity for changes in canonical Wnt signalling,
we investigated whether MSI2 altered β-catenin translocation
using immunofluorescence (IF). Increased MSI2 overexpression
caused nuclear localisation of β-catenin in MCF7 (Fig. 3b),
further corroborating MSI2—and more generally, the module’s
role—in the Wnt signalling cascade. Furthermore, the increasing
expression of MSI2 with proximity to tumour, alongside its
effects on β-catenin translocation, is consistent with the module-
specific enrichment of components involved in formation of the
β-catenin:TCF-transactivating complex.
MSI2 abundance is associated with tumour grade. Having
implicated MSI2 in the Wnt pathway and partially validating that
the module is a candidate Wnt-driven module, we were interested
in exploring whether MSI2 protein abundance correlated with
other clinical traits. A consecutive series of 232 invasive breast
cancers was evaluated using in-house TMAs (Supplementary
Fig. 1) to assess the status of MSI2 protein abundance in a larger
cohort of breast cancer patients. MSI2 protein expression was
seen in both the cytoplasm and the nucleus. MSI2 protein
abundance was significantly negatively associated with ER and
PgR status (p< 0.05; Methods section; Supplementary Fig. 1).
Representative staining of the TMAs is shown in Supplementary
Fig. 2.
To characterise the functional consequences of increased MSI2
expression in vivo we used a transwell assay to evaluate
migration. MSI2-GFP-expressing MCF7 cells exhibited a sig-
nificant 104% increase in migration relative to control cells
expressing GFP alone (95% confidence interval= 11.6% to
198.4% increase; Welch’s t test; p< 0.05; Fig. 4a). The number
of invasive cells also increased by 77% compared to the GFP
controls in MCF7 (95% confidence interval= 23.6% to 130.8%
increase; Welch’s t test; p< 0.05; Fig. 4b). Similar results were
observed in the MDA-MB-231 cell line over-expressing a MSI2-
GFP fusion (Welch’s t test; p< 0.05 for both; 193 and 291%
increase for migration and invasion, respectively; Fig. 4c, d). The
MSI2-knockdown MCF7 clones exhibited the reverse effect in the
migration and invasion assays (Fig. 4e, f). The knockdown cell
line was further assessed for proliferative capacity by the cell
counts at different days. By day 5, MSI2-knockdown cells
exhibited significantly decreased proliferative capacity, in contrast
to the controls (Welch’s t test; p< 0.05; Supplementary Fig. 3).
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Fig. 3 MSI2 overexpression activates the Wnt cascade. a MSI2 overexpression results in a significant 1.5-fold linear increase in TOPFLASH Luciferase
activity, relative to Flag control (paired Student’s t test; p< 0.05; please note the log scale). b MSI2 overexpression mediates β-catenin localisation to the
nucleus, with no change in the total intracellular β-catenin levels. Left panel: representative immunofluorescence image of control MCF7 (nucleus is
highlighted with blue DAPI staining; β-catenin is stained green; and MSI2 is red). β-catenin is largely localised to the membrane and the cytosol. Right
panel: representative immunofluorescence image of MCF7 MSI2 overexpression clones, with β-catenin localisation to the nucleus
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Fig. 4 MSI overexpression increases migration and invasion of MCF7 and MDA-MB-231 MCF7-expressing GFP and MSI2-GFP were counted by Vi-cell-XR,
and equally plated on transwells with and without Matrigel. Migration a and invasion b qualities were assessed by counting cells 48 h after initial plating.
MSI2 overexpression causes an increase in migration and invasion (Welch’s t test; p< 0.05). Box plots of all replicates within each experiment (n= 3) are
depicted. MDA-MB-231-expressing GFP and MSI2-GFP were plated on transwells with and without Matrigel. 48 h after initial plating, the transwells were
counted for migration c and invasion d. MSI2 increased both the migrative capabilities and invasive tendencies of MDA-MB-231 (Welch’s t test; p< 0.05).
As with the MCF7, box plots of all replicates within each experiment (n= 4) are depicted. Migration e and invasion f were also assayed in MCF7 shRNA
control and shRNA MSI2, respectively. The knockdown clones presented the opposite effect, with a significant decrease in the migration and invasion
ability of MCF7 (Welch’s t test; p< 0.05). Proliferation assay results are summarised in Supplementary Fig. 3
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SPAG5 abundance is associated with tumour grade. Analogous
to our previous analysis, we were interested in whether any signal
transduction pathways were over-represented in Module 2, a 371-
gene module (all genes are listed in Supplementary Data 6). None
were discovered; full over-representation analysis is available in
Supplementary Data 7. Moreover, the module appears to be
enriched in gene sets relating to oxidative phosphorylation, the
electron transport chain, the proteasome and metabolism, more
generally. This suggests that this module is enriched for genes
necessary for cell survival and possibly, proliferation. Subse-
quently, we elected to study one gene from this module with
increasing expression with proximity to tumour. In particular, we
decided to further explore the role of SPAG5 protein in breast
tumourigenesis (for which we had TMA data), as it has been
previously implicated in the maintenance of spindle-pole integ-
rity, efficient chromosomal alignment and cell proliferation27.
SPAG5 has been shown to interact with the mitotic spindle
apparatus and is expressed in most human cell lines and
tissues28, 29. The protein produced by the gene is a homodimer,
with a globular head domain that interacts to form aster-like
structures, which attach to microtubules in the mitotic spindle.
To further explore the role of this gene in breast cancer, FFPE
TMA blocks consisting of invasive breast cancers from 234
patients, were analysed (Supplementary Fig. 1). Immunohisto-
chemical staining with an anti-SPAG5 antibody revealed that
tumour grade was significantly and positively (p< 0.05; Methods
section) associated with SPAG5 protein levels.
Discussion
Identifying genomic alterations in mammary epithelial cells that
precede breast carcinoma will allow us to better understand
carcinoma development and heterogeneity. By obtaining and
profiling morphologically normal epithelial samples at various
distances from the tumour (and a sample from the tumour itself),
we were able to draft a spatial map of the genomic events and
transcriptomic alterations that occur along the mammary duct
(leading up to and including the tumour).
In particular, using aCGH, we confirmed that the region sur-
rounding the tumour is remarkably unstable with heterogeneous
and varied genetic alterations; consistent with previous reports of
LOH events and allele imbalances in adjacent-to-tumour epi-
thelium (compared to normal breast tissue from the same
patient)1, 2. Furthermore, we have shown that genomic alterations
(in the form of copy number alterations) do not explain much of
the expression perturbation that is observed with proximity to
tumour. Through principal component analysis of the gene
expression matrix, we observed that the first transcriptomic
principal component corresponds directly to proximity to
tumour. As we discuss below, we showed that transcriptomic
alterations in spatially informative coexpression modules are
likely more important than the paracrine influence of the tumour
and this perturbation may precede tumourigenesis. Furthermore,
the enrichment of somatic mutations in genes that correlate with
proximity to tumour suggests a non-paracrine mechanism
underlying the dysregulation. If paracrine effects predispose cells
to increased mutations, all genes should be affected equally (i.e.
no enrichment). Furthermore, if a paracrine effect is at play, it is
also unlikely that it will extend so far beyond the tumour as our
samples were taken and that it would produce a similar effect
regardless of the adjacent tissue type (fibrous, adipose, epithelial,
etc).
To the best of our knowledge, this represents the first direct
evidence of field cancerization surrounding the primary tumour.
All current evidence of global gene expression dysregulation in
adjacent-to-tumour (but not necessarily in the same duct system)
epithelium depends on comparisons to external patient data sets
(such as breast tissue from patients with mammary hypertrophy
undergoing reduction mammoplasty, from cohorts with atypical
hyperplastic proliferative lesions, or simply just healthy indivi-
duals without cancer unmatched for clinical traits)9, 10. Other
studies, that demonstrate widespread differential gene expression
between patient-matched breast normal tissue, have confounding
variables: such as analysis of bulk tissue of various types instead of
more pure microdissected epithelial samples11. Unlike previous
studies, we have further demonstrated that gene expression can
identify from where the epithelial sample was obtained relative to
the tumour (with a cross-validated average AUC= 0.74). This is
the strongest evidence that epithelial samples surrounding the
tumour differ from epithelial samples from the contralateral duct
within an individual. The discriminative ability of the classifier
suggests that these differences (or perhaps, perturbations) are
shared across the cohort. Combined with the inability of copy
number alterations to explain these transcriptomic patterns, this
suggests that other forms of dysregulation (such as single-
nucleotide variation, miRNA or epigenetic modifications) may be
the primary drivers of initiation and progression in early tumour
development.
Subsequently, using spectral co-clustering, we identified
biclusters (i.e. coexpressors) with perturbations that may be
among the first molecular alterations shared by breast cancer
patients, preceding common aberrations detected by aCGH.
Genes in these biclusters were a priori selected as informative for
proximity-to-tumour label (prior to the co-clustering). We
demonstrate that the genes in modules with significant correla-
tion to proximity to tumour were more likely to be mutated in
breast cancer patients (compared to background genes in non-
significant modules), suggesting that this perturbation is a con-
sequence of field cancerization (rather than paracrine influence
from the primary tumour). As these genes are enriched for
somatic mutations in tumours (i.e. they are more likely to be
mutated), this further suggests a functional role for many of these
genes in tumour development and progression. Furthermore, in
an analysis by Rheinbay et al.30, deep sequencing of 360 primary
breast cancers revealed six promoters (TBC1D12, LEPROTL1,
ZNF143, RMRP, ALDOA and FOXA1) that contained single-site
mutational hotspots (three or more mutations at a single site).
Three genes (ZNF143, ALDOA and LEPROTL1) were among the
top 30% of genes that are univariately informative of the
proximity-to-tumour label. Two genes (TBC1D12 and RMRP)
were not on the expression platform; FOXA1 was not informative
of the spatial label for the samples and was the only gene (among
the 4 present on the platform) with the mutational hotspot not
located in or adjacent to the 5′ untranslated region. Two genes
(ALDOA in module 5 and LEPROTL1 in module 2) also belonged
to modules that significantly and positively correlated with
proximity to tumour. Thus, non-coding single-nucleotide muta-
tions may be responsible, in part, for the observed field
cancerization.
Moreover, other genes in high-correlation modules have been
previously implicated in early carcinogenesis. For instance,
MAPK14 (also known as p38) is present in module 2 and
Gauthier et al.12 have noted increased activated phospho-p38
staining intensity in the adjacent normal epithelium to DCIS
compared with normal epithelium from reduction mammoplasty
specimens. This is consistent with the positive correlation of
module 2 with proximity to tumour. MAPK14 acts to stabilise the
immediate-early gene COX2, also implicated in tumourigenesis12.
We found associations for two of these coexpression modules
with signalling cascades, and correlated two genes with clinical
covariates. In particular, we noted the presence of MSI2 in
module 16, which was positively correlated with proximity to
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tumour and enriched for genes relating to the formation of the
beta-catenin:TCF-transactivating complex (of the Wnt signalling
cascade). Notably,MSI2 is located at 17q23.2-23.3 (55.1–55.9 Mb)
24; part of an amplicon (17q22-24.2) whose gain is a predictor of
invasion in DCIS and of nodal metastasis in invasive duct car-
cinoma (IDC)31. We were able to directly implicate MSI2 in Wnt
activation, with overexpression leading to β-catenin localisation
to the nucleus and increased luciferase activity (i.e. pathway
activity) using a TCF/LEF-1-dependent luciferase reporter con-
struct. This suggests that Wnt signalling may be one of the earliest
changes in breast cancer, as well as tumour development and
progression. Studies in neuroblastoma and ovarian cancer also
revealed amplification of the MSI2 genomic region, suggesting a
role for both gene and genomic interval in oncogenesis and
tumour progression32–34. More generally, this hints at the pos-
sibility that Wnt signalling may be implicated in early changes in
other tumour types as well. Looking at another module that is
both significantly and positively correlated with proximity to
tumour (module 2), we note the presence of SPAG5, which
positively correlates with tumour grade. Module 2 includes genes
whose abnormal function has been directly associated with breast
cancer, such as MAPK14, BRCA1, CDH1, HIF1A, CDKN2A and
other members/regulators of the CDK family. It is important to
note that membership to a module that positively correlates with
proximity to tumour may be indicative of either a function in
early tumourigenesis (e.g. MAPK14) or a protective role in
response to the increased stress and dysregulation of the cellular
environment (as genes in these modules are enriched for somatic
mutations in tumours with both gain-of-function and loss-of-
function consequences).
Here, in summary, we presented the first spatially compre-
hensive CNA and mRNA characterisation of morphologically
normal epithelium from primary breast cancer patients of mul-
tiple molecular sub-types. Our results emphasise previous find-
ings that Wnt signalling may be one of the earliest changes in
breast cancer and we identify a new gene involved in the Wnt
pathway. Our discovery of SPAG5 as an early gene suggests the
presence of increasing chromosomal alterations with decreasing
distance to tumour; consistent with our CNA observations. This
study, however, did not address whether common epigenetic field
effects, single-nucleotide non-coding variation, miRNA regula-
tion or shared telomere dysfunction may influence the observed
transcriptomic perturbation with increased proximity to tumour.
However, there is evidence in the expression data indicating field
alterations and that CNAs do not readily explain this field can-
cerization. Our results have important implications for cancer
screening and prevention and could lead the way to new ther-
apeutic approaches and targets.
Methods
aCGH and gene expression dataset preparation. Fifteen patients undergoing
mastectomy for biopsy-proven carcinoma were recruited at the Princess Margaret
Cancer Center, University Health Network (Toronto, ON, Canada) from 2005 to
2008. Informed consent was obtained after the nature and possible consequences of
the study were explained. Inclusion criteria were defined as tumours at least 2 cm in
diameter as measured by imaging, and located at least 3 cm from the nipple.
Institutional REB approval was obtained prior to patient recruitment. Clinico-
pathological data was obtained for all patients for whom all eight samples (four
expression and four aCGH) passed quality control (QC) at the microarray centre
(n= 8). During surgery, prior to removal of the breast, a ductoscopy procedure was
performed using a 0.7 mm mammary ductoscope (MF2-707, MD Fibertech Co,
Japan). Details of tissue sampling are described in the main text. All tissues
obtained were bisected, with one half snap frozen and the other half formalin-fixed
and paraffin-embedded (FFPE). Normal lymph node tissue was also obtained for
control DNA. Snap frozen tissues were sectioned at 8 μm thickness using a
microtome and lightly stained with hematoxylin. Histological identification of
tumour and normal ducts was confirmed by a pathologist. Needle-microdissection
was performed by a pathologist with a stereoscopic dissecting microscope for both
tumour and ducts to ensure minimal stromal contamination of epithelial cells.
DNA and RNA were extracted from microdissected tissue using the Qiagen All-
prep RNA/DNA Micro Kit (Qiagen, Mississauga, ON, Canada).
Array comparative genomic hybridisation and analysis. Whole genome
amplification was performed using the single-cell comparative genomic hybridi-
sation protocol as described previously35. Amplified DNA was labelled using the
Agilent Genomic DNA ULS Labeling Kit and hybridised using the aCGH Hybri-
dization Kit on Agilent Human 244k arrays (Agilent Technologies, Mississauga,
ON, Canada) as per manufacturer’s standard protocol. Pooled lymph node tissue
from patients was used as controls and processed in a similar fashion. Raw
microarray image files were extracted using Agilent Feature Extraction Software
(v9.5). Data were imported into Agilent Genomic Workbench v7.0.4.0 (Agilent
Technologies, Santa Clara, CA, USA) for QC analysis. QC metrics were generated
for all samples; none were excluded from subsequent analyses. aCGH data were
subsequently analysed and visualised using rCGH v1.2.2 (bioconductor v3.3);
package code and resources were modified to work with hg17 (genome build of
data).
Expression microarray protocol and analysis. Global cDNA Whole-Human
Genome 4 × 44 K Microarray (Agilent) gene expression profiling was performed on
the same tissue specimens previously mentioned, as described elsewhere36. Briefly,
100 ng of mRNA were reverse transcribed using Superscript II reverse transcriptase
(Invitrogen Canada, Burlington, ON) while incorporating Cy3-dCTP or Cy5-dCTP
(NEN, Boston, MA, USA). Raw microarray image files were extracted using Agilent
Feature Extraction Software (v9.5). Microarray data were pre-processed and nor-
malised using agilp v3.4.0 (bioconductor v3.3); only probes that matched to a gene
symbol were included. In case of multiple ID mappings, the average was calculated
between the matching probes, with no filtering on variance or expression threshold.
Six samples (4_D1, 4_O1, 8b_T, 10_D1, 10_D2 and 22_D1) were excluded, after
QC, and were defined as outliers using a sum of standard error boxplot.
Bioinformatic analyses. To quantify the variance explained by CNAs, linear
regression was performed with R v3.2.2. After filtering based on intersection of
genes present in both the processed mRNA abundance and aCGH data, residuals
were obtained for each sample along duct leading to tumour (from the expression
—contralateral sample equation) and a linear regression model was built in the
form of residuals—aCGH data. Both residuals and aCGH came from the same
epithelial sample (i.e. at the same distance from the tumour). Principal component
analysis of the expression matrix was completed using base functions of R v3.2.2
and visualised using ggbiplot (freely available at, https://github.com/vqv/ggbiplot/).
We implemented the multi-label classifier using scikit-learn 0.18 using OneVs-
RestClassifier with a C-Support Vector Classification linear-kernel estimator. ROC
curves were drawn by considering each element of the label indicator matrix as a
binary prediction (microaveraging). Spectral co-clustering was also performed
using scikit-learn 0.18, with feature agglomeration, incorporating a ward linkage
criterion and a Euclidean affinity. The number of clusters was optimised to increase
overlap of sample biclusters with known distance annotations, as quantified using
the adjusted Rand score.
MSI2 overexpression. A total of 5 μg MSI2-GFP and GFP vectors (pCMV6-
MSI2-AC-GFP and pCMV6-AC-GFP from Origene, Rockville, MD, USA) were
transfected into MCF7 and MDA-MB-231 cells (source: ATCC) using endofectin
transfection reagent (Genocopoeia, Rockville, MD, USA) according to the manu-
facturer’s instructions. Expression was determined by fluorescence microscopy,
western immunoblotting and qRT-PCR. Cell lines were authenticated and quality
controlled at ATCC.
Migration and invasion assays. For the migration and invasion assays, stable
(overexpression) clones were selected with G418 (2.3 mg/ml) for 5–10 passages (for
both MCF7 and MDA-MB-231). Stable MSI2-knockdown clones were established
using shRNA (Origene) using a lentiviral transfection in 293 T cells, followed by
transduction and selection with puromycin (0.6 μg/ml). Knockdown of MSI2
expression in individual clones was confirmed by RT-PCR. For invasion and
migration assays, 24-Transwell plates (8-μm pore size; BD Biosciences, Franklin
Lakes, NJ, USA) were coated with Matrigel (BD Biosciences) or without a coating,
respectively. 105 cells were plated on the upper side of the inserts, and allowed to
migrate or invade to the underside of the insert over 48 h. Inserts were fixed and
stained. The total number of cells on the underside of the insert was counted at the
microscope. Each experiment was performed in triplicate. Welch’s t test was used
to assess significance.
Immunofluorescence staining. MCF7 cells were grown on 22mm round collagen
type I coated coverslips (BD Biosciences) until 70% confluent. The cells were then
fixed with 4% paraformaldehyde solution for 15 min at room temperature. Fixed
cells were permeabilised by washing twice in PBS with 0.01% Tween20 for 5 min.
Blocking was carried out with 1% BSA in the above PBS/Tween solution for 30 min
at room temperature. Cells were then incubated in a mixture of the two primary
antibodies (rabbit against MSI2 and mouse against β-catenin from BD transduction
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lab #610153; 1:100 dilution in 1% BSA/PBS/Tween overnight at 4 °C). Following
three 3-min washes in ice cold PBS, fluorescently labelled secondary antibodies
were applied for one hour. Using FV10-ASW version 2.1c imaging software, each
image was captured sequentially with four channels (Cy3, FITC, DAPI and DIC) to
eliminate crosstalk between channels. All images were captured at ×60
magnification.
Luciferase assay. MCF7 cells were transfected with 400 ng of the TOP Luciferase
reporter transgene, 40 ng of a constitutive renilla luciferase transgene and 500 pg or
50 ng of flag-MSI2 using Lipofectamine LTX with Plus Reagent (Life Technologies)
according to the manufacturer’s instructions. Cell lysates taken after 48 h and
luciferase activities were determined using the Dual-Luciferase Reporter Assay
System (Promega) according to manufacturer’s instructions. Three successful
assays (n = 3 replicates each) were completed demonstrating that an increase in
Wnt signalling corresponded with MSI2 overexpression. However, only two were
plotted and analysed (one way ANOVA; paired Student’s t test) as the FOP
negative control was unsuccessful for 1 of the 3 trials.
MSI2 TMA. Immunohistochemical analysis of MSI2 expression in breast cancer
cells was performed. Briefly, slides sectioned from an in-house (UHN) TMA were
dewaxed in xylene and rehydrated through alcohol to water. The TMAs consisted
of a consecutive series of FFPE invasive breast carcinomas (n= 234 but two cases
were technically unsatisfactory) collected from a single institution (UHN) in 2006.
Endogenous peroxidase was blocked with 3% hydrogen peroxide for 10 min.
Microwave antigen retrieval was carried out in 10 mM citrate buffer pH6. Endo-
genous biotin was blocked with Vector’s biotin blocking kit and slides were then
incubated with MSI2 (Millipore EP1305Y, Etobicoke, ON, Canada) at a con-
centration of 1:300 at 4 °C overnight. After washing in PBS, biotinylated anti-rabbit
IgG incubations were carried out. Immunoreactivity was revealed by incubation in
DAB substrate (Vector labs, Burlington, ON, Canada) for 3 min. Slides were
counterstained in Mayer’s hematoxylin. MSI2 immunohistochemical staining was
evaluated using light microscopy. Cases were blindly scored by a pathologist using
the Allred Scoring system as described37. Available clinical data was used to
compare MSI2 expression with tumour grade, stage and receptor status. Pearson’s
correlation (point biserial correlation for binary variables) was used to assess
association at a 5% significance level.
SPAG5 TMA. Anti-SPAG5 rabbit antibody (HPA022008) was purchased from
Sigma-Aldrich (St. Louis, MO, USA). FFPE TMA blocks of 234 UHN invasive
breast cancers were stained with the antibody using the manufacturer’s protocol.
Scoring of immunohistochemical staining was performed using a semi-quantitative
scoring system. TMAs were analysed in a blinded manner by a pathologist using a
four-point semi-quantitative scale (0, 1+, 2+, 3+) for intensity. The intensity of
staining was scored as 3+(strong), 2+(intermediate), 1+(weak) and 0 (no staining).
Cases that were stained for SPAG5 showed homogeneous staining of all cancer cells
within the core; the percentage positivity was 100%. Tissues showed moderate
cytoplasmic positivity. As with MSI2, Pearson’s correlation (point biserial corre-
lation for binary variables) was used to assess association at a 5% significance level.
Data availability. Gene expression and aCGH data has been deposited by M.A.
and S.J.D. in the National Center for Biotechnology Information’s (NCBI’s) Gene
Expression Omnibus (GEO) and are accessible through GEO Series accession
number GSE72653 (SuperSeries consisting of patient-matched gene expression
[GSE72644] and aCGH [GSE72652] data). Correspondence and requests for
materials should be addressed to S.J.D.
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